Loading...
•
Sep 30, 2025
IDEXX Q3 2025 Earnings Report
IDEXX delivered strong Q3 results with double-digit growth in revenue and earnings.
Key Takeaways
IDEXX Laboratories posted a robust Q3 2025, achieving double-digit growth in revenue, earnings, and operating income, driven by strong performance in CAG Diagnostics and significant placements of inVue Dx instruments.
Revenue reached $1.105 billion, driven by 13% reported growth.
EPS was $3.40, with adjusted EPS at $3.22.
Net income rose to $274.6 million.
Strong demand for IDEXX inVue Dx and VetLab consumables supported performance.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
IDEXX raised its full-year 2025 revenue and EPS guidance, driven by strong recurring revenue and instrument placement performance.
Positive Outlook
- 2025 revenue guidance raised to $4.27B–$4.30B.
- Expected organic revenue growth of 8.8%–9.5%.
- CAG Diagnostics recurring revenue expected to grow 7.5%–8.2% organically.
- EPS guidance raised to $12.81–$13.01.
- Operating margin outlook increased to 31.6%–31.8%.
Challenges Ahead
- Rapid assay product sales continued to decline.
- Impact of recent U.S. tax law changes added $0.09/share in tax expense.
- Free cash flow conversion slightly impacted by higher capital expenditures.
- Higher R&D and employee incentive costs increased operating expenses.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...